Liu Ying, Liu Limei, Ma Xin, Yin Yupeng, Tang Bo, Li Ziyi
*Jilin Provincial Key Laboratory of Animal Embryo Engineering, the Centre for Animal Embryo Engineering of Jilin Province, College of Animal Science and Veterinary Medicine, Jilin University, 5333 Xi An Da Lu, Changchun, Jilin 130062, China.
Biosci Rep. 2013 Mar 28;33(2):e00032. doi: 10.1042/BSR20120023.
MSCs (mesenchymal stem cells) are a stem cell source that can be easily obtained from bone marrow. Despite the increasing importance of the pig as a large animal model, little is known about foetal pMSCs (porcine MSCs). In this study, we observed the gene expression of pluripotent markers in foetal pMSCs and the capacity of pMSCs to differentiate into adipocytes, osteocytes and neural-like cells using quantitative RT-PCR (reverse transcription-PCR), normal histological staining and immunohistochemistry. Foetal pMSCs have either a spindle or a flattened shape, and flow cytometry revealed the expression of the MSC-related proteins CD44 and CD105 (endoglin) but not CD34 and CD45. pMSCs express pluripotent markers such as Oct4 (octamer-binding transcription factor 4) and Nanog at the protein and mRNA levels. qRT-PCR (quantitative real-time PCR) analyses revealed that pMSCs expressed nestin [for NSCs (neural stem cells)]. Immunocytochemical and RT-PCR data showed that 29% and 23% of pMSCs expressed MAP2 (microtubule-associated protein 2) for neurons and β-tubulin III (Tuj1) for immature neurons, respectively, after induction of neural differentiation. These findings demonstrate the plasticity of pMSCs and their potential for use in cellular replacement therapy for neural diseases.
间充质干细胞（MSCs）是一种可轻易从骨髓中获取的干细胞来源。尽管猪作为大型动物模型的重要性日益增加，但对于胎儿猪间充质干细胞（pMSCs）却知之甚少。在本研究中，我们使用定量逆转录聚合酶链反应（RT-PCR）、常规组织学染色和免疫组织化学，观察了胎儿pMSCs中多能性标志物的基因表达以及pMSCs分化为脂肪细胞、骨细胞和神经样细胞的能力。胎儿pMSCs呈纺锤形或扁平形，流式细胞术显示其表达与MSC相关的蛋白CD44和CD105（内皮糖蛋白），但不表达CD34和CD45。pMSCs在蛋白质和mRNA水平表达多能性标志物，如八聚体结合转录因子4（Oct4）和Nanog。定量实时聚合酶链反应（qRT-PCR）分析显示，pMSCs表达巢蛋白[用于神经干细胞（NSCs）]。免疫细胞化学和RT-PCR数据表明，在诱导神经分化后，分别有29%和23%的pMSCs表达神经元的微管相关蛋白2（MAP2）和未成熟神经元的β-微管蛋白III（Tuj1）。这些发现证明了pMSCs的可塑性及其在神经疾病细胞替代治疗中的应用潜力。
